SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohen's recent cryptic social media posts are driving intense speculation among investors about an imminent, monumental acquisition or strategic move, leveraging GameStop's substantial cash reserves. This dynamic fuels a fierce debate between ardent holders anticipating a massive short squeeze and skeptics citing ongoing price suppression and the absence of concrete company details.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community hotly debates the immense potential of its advanced GaN and SiC power platforms for next-gen AI data centers, particularly its role in NVIDIA's AI ecosystem. Despite the recognized breakthrough technology addressing critical efficiency needs, investors are expressing significant concern over the current absence of definitive, revenue-generating contracts, especially ahead of its upcoming earnings report.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating US-Iran tensions are a primary catalyst, leading the community to intensely debate the potential for military action and a subsequent surge in oil prices, positioning Exxon Mobil as a key beneficiary. This geopolitical focus, coupled with the company's strong production in regions like Guyana and strategic moves into carbon capture, is driving bullish sentiment despite some concerns about the stock's rapid ascent.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with strong community enthusiasm surrounding its anticipated BLA resubmission for deramiocel by the end of February, driving speculation for accelerated FDA approval and potential buyout interest, all while institutional ownership continues to increase.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is generating significant buzz as its community actively accumulates the token, driven by speculation around potential ETFs and its perceived status as the next-generation Layer 1 blockchain. Enthusiasts highlight its superior speed and efficiency compared to rivals, with many viewing current price levels as a prime buying opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following ANKTIVA's conditional marketing authorization across 33 European countries and accelerated approval in Saudi Arabia for lung cancer, sparking community excitement over immediate global revenue growth and an anticipated short squeeze, as many view Dr. Patrick Soon-Shiong's immunotherapy platform as an "unstoppable" force in cancer treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RZLV I have always wondered since the  $GME pump and dump, how much social equity influences stock prices ??? 🤔 Don&#39;t get caught up in the hype, know your exit plan 🍻

Ernesto Sierra

EltonCarr

Azteca

StockTwits Web

Rezolve AI Limited

 pump and dump, how much social equity influences stock prices ??? 🤔 Don't get caught up in the hype, know your exit plan 🍻

@Dayslayer247 How much and how great is social influence on it now?
It is a peanut to me now. Not big enough to discuss now.

StockTwits For Android 

 How much and how great is social influence on it now?
It is a peanut to me now. Not big enough to discuss now.

sam T

@Dayslayer247 what pump and dump? You mean them removing the buy button?
Maybe include that when you tag us with bullshit comments like this.

The Goat

Brandon Baker

StockTwits for iOS

 what pump and dump? You mean them removing the buy button?
Maybe include that when you tag us with bullshit comments like this.